Voiding Disorders
Conditions
Keywords
OAB
Brief summary
Our study included 60 patients with idiopathic OAB and treated with solifenacin 5mg twice daily for one month. After improvement of their condition, we divided the responders into 2 groups, group I stopped the drug suddenly, while group II underwent gradual weaning of the drug.
Detailed description
We started an open-label, prospective, two-arm, randomized controlled trial at Beni-Suef University, from January 2018 to January 2019, including 60 patients suffering from OAB symptoms. Patients were recently diagnosed with idiopathic OAB which was not treated prior to enrollment. All participants signed written informed consents. The study protocol was approved by the ethics committee of our faculty. Patients were allocated into 2 equal groups (30 patients in each group) according to a computer-generated random numeric table after exclusion of those who are not eligible or refused to be included in the study
Interventions
gradual weaning of drug vs. stopping
Sponsors
Beni-Suef University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
60 patients with idiopathic OAB and treated with solifenacin 5mg twice daily for one month. After improvement of their condition, we divided the responders into 2 groups, group I stopped the drug suddenly, while group II underwent gradual weaning of the drug.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* OAB patients. * Recently diagnosed.
Exclusion criteria
* Previous trials of treatment * UTI, stones, tumors, or Infravesical obstruction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| improvement | 1 month | decrease voiding times |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| recurrence of symptoms | 3 months | increase in voiding times after improvement |
Countries
Egypt
Outcome results
None listed